IMOS Upcoming Events

Monthly Teleconferences:

Wed., April 25, 2012
Wed., May 23, 2012
Wed., June 27, 2012
Wed., July 25, 2012
Wed., August 22, 2012
Wed., September 26, 2012
Wed., October 24, 2012
Wed., November 28, 2012

Reception for IMOS Members:
The Best of ASCO
Thursday, July 12, 2012
4:30–6:30 pm
Hyatt Regency Chicago

Fellows Research Competition Dinner
(for fellows only):

Thursday, August 23, 2012

IMOS Annual Membership Conference:
Friday, October 26, 2012
Chicago Marriott Schaumburg

For more information, go to

2012 IMOS
Board of Directors

Timothy M. Kuzel, MD, FACP
Northwestern University

Ann L. Mellott, MD
Hematology-Oncology Associates of Illinois

Bruce R. Kaden, MD
Illinois Cancer Specialists

Immediate Past President
Paul A. S. Fishkin, MD
Illinois Cancer Care

Diane Gerards-Benage, CMPE
Quincy Medical Group

Joseph J. Kash, MD
Edward Cancer Center

Donna Krueger, RN, OCN
Illinois Cancer Specialists

Pankaj Kumar, MD
Illinois Cancer Care

Gary MacVicar, MD
Northwestern University

IMOS Corporate Members

(as of 3/30/12)


Bayer Healthcare


Amgen Inc.
Genentech, Inc.
Lilly Oncology
Millennium, The Takeda
  Oncology Company
Novartis Pharmaceutical
Onyx Pharmaceuticals

Thank you for the value you bring to IMOS!

— Spring 2012 —

President's Message:
IMOS 2012: Goals, Plans, and the Value of Membership
Timothy M. Kuzel, MD, FACP

Timothy M. Kuzel

As this is my initial column for the Illinois Medical Oncology Society (IMOS) newsletter, I would like to thank you for demonstrating your faith in me by supporting my election to President. It is my pleasure to have the opportunity and honor to work with you and our colleagues to advance the goals of oncology through our organization in the state of Illinois.

A major goal of mine during the next two years will be to raise the profile of IMOS. Although most cancer care professionals are aware that while the American Society of Clinical Oncology, the American Society of Hematology, and other national organizations lead efforts to influence public health policy as it relates to the practice of hematology and oncology, many do not appreciate the advantages of joining and actively participating in a statewide society.

Read more.

2012 Educational Programs Announced

In 2011, IMOS sponsored the State Society Education Series, which marked its inaugural year with four exciting education programs. Now IMOS is planning timely and relevant programs for 2012, starting with an issue that is growing in importance to many of us in the practice of oncology.

Watch for a podcast series coming soon called "Physician Service Agreements: Evolving Models." Listen to our podcasts at your convenience to gain the different perspectives of four oncology professionals who have experienced creating physician service agreements in the oncology community.

Read more.

Jurisdiction 6 Part B News from Wisconsin Physicians Service (WPS)

WPS Announces Recent Changes to Edits to Monitor High Dollar Claims
Changes to Multi-Carrier System (MCS) edits will affect services that are subject to high dollar claim review. To ensure the services provided and billing is appropriate, WPS Medicare will request documentation on claims when the approved to–pay amount is $7,500 or more. If it is your practice to send records before receiving the additional documentation request (ADR) letter, please keep this threshold in mind to avoid unnecessary submission of documentation.

WPS Updates Certain Medicare Policies for March 2012
New Medicare policies effective March 17, 2012, include: Acute Inpatient Services versus Observation (Outpatient) Services and Proton Beam Therapy. Revised policies include: Chemotherapy Drugs and their Adjuncts—Effective 02/01/2012; Circulating Tumor Cell Marker Assays—Effective 02/15/2012; Independent Diagnostic Testing Facilities (IDTFs)—Appendix A—Effective 01/01/2012; Magnetic Resonance Imaging—Effective 01/01/2012. View details about these policy updates on the WPS website.

Read more.

Guide to Patient Assistance and Reimbursement Programs

As a Regular, Group, or Associate member of IMOS, you may access the resources of the Association of Community Cancer Centers (ACCC). To view ACCC's digital edition of the 2012 Patient Assistance and Reimbursement Guide, which brings together information on pharmaceutical and non-pharmaceutical patient assistance programs and reimbursement resources, click here. You will need to create a password and log in.

News from IMOS Corporate Members

The FDA approved new indications for Prolia® (denosumab) (Amgen, as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor (AI) therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In patients with prostate cancer, Prolia also reduced the incidence of vertebral fractures. Denosumab is a monoclonal antibody that binds to RANKL, a protein involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.

Read more.

SCOS members


For more information about Illinois Medical Oncology Society (IMOS)
go to or call 301.984.9496, ext. 218

You are receiving this message because you are affiliated with IMOS and we believe you will benefit from this information.